Sign inJoin waitlistJoin the waitlist

Natalie Callander

Professor · University of Wisconsin Hospitals and Clinics

Credentials: · · · · ·

History

University of Wisconsin Hospitals and Clinics
Present

Hematology and Medical Oncology
University of California (San Diego) Medical Center
1988–1991
New York University
1985–1988
Tufts University School of Medicine
1981–1985

Research

Lenalidomide after stem-cell transplantation for multiple myeloma
New England Journal of Medicine · 2012 · 909 citations
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised…
The Lancet Oncology · 2010 · 823 citations
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
The Lancet · 2016 · 711 citations

Shaji Kumar
33 papers
Peiman Hematti
31 papers
Luciano Costa
29 papers
Parameswaran Hari
27 papers
Kelly Godby
26 papers
Binod Dhakal
20 papers
CF
Cesar Freytes
19 papers
SB
Susan Bal
18 papers
Fotis Asimakopoulos
17 papers
Saurabh Chhabra
17 papers
Paul Richardson
16 papers
Caitlin Costello
15 papers

Clinical trials

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Principal investigator · Recruiting · Phase 1, Phase 2
Natalie Callander
2026–2029
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Principal investigator · Recruiting · Phase 3
ECOG-ACRIN Cancer Research Group
2019–2029
Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Principal investigator · Completed · Phase 1
Cellectar Biosciences, Inc.
2015–2022
Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2006–2014